Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 10/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25879649 | 0.92 | CFD (0.85) | CFDF11TPSB2SUCNR1ABCB1 | |
| SCHEMBL21455332 | 0.84 | CFD (1.00) | CFDF11TPSB2SUCNR1 | |
| SCHEMBL21455336 | 0.83 | CFD (0.79) | CFDF11TPSB2SUCNR1ABCB1 | |
| SCHEMBL25879656 | 0.78 | CFD (0.53) | CFD | |
| SCHEMBL21455345 | 0.78 | CFD (0.59) | CFDSUCNR1 | |
| SCHEMBL25879657 | 0.76 | CFD (0.48) | CFDALDH1A1MAPTPOLBKDM4E | |
| SCHEMBL24200068 | 0.72 | CFD (0.49) | CFDALDH1A1MAPTF11TPSB2 | |
| SCHEMBL21439579 | 0.66 | CFD (0.58) | CFDALDH1A1MAPTF11TPSB2 | |
| SCHEMBL21439643 | 0.66 | CFD (0.73) | CFDF11TPSB2SUCNR1 | |
| SCHEMBL21437767 | 0.66 | CFD (0.59) | CFDALDH1A1MAPTF11TPSB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | CFD 17/4885ALDH1A1 1047/4885MAPT 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.